Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, RN-BSN, MSN, NP-C, discuss the current standard of care for both high- and low-risk patients with newly diagnosed or recurrent/refractory multiple myeloma who are initially not eligible for autologous stem-cell transplant and who subsequently become transplant-eligible.
Current Standard of Care for Patients with Multiple Myeloma Based on Their Eligibility for Autologous Stem-Cell Transplant
Video Library —April 23, 2020
Categories:
Interview with the InnovatorsAdvanced Practice Provider Chief, Winship Cancer Institute,
Emory University,
Atlanta, GA
Emory University,
Atlanta, GA
Clinical Pharmacy Specialist, Multiple Myeloma, and PGY2 Oncology Residency Research Coordinator,
Winship Cancer Institute, Emory Healthcare,
Atlanta, GA
Winship Cancer Institute, Emory Healthcare,
Atlanta, GA
Nurse Practitioner, Inpatient and Outpatient Malignant Hematology,
Levine Cancer Institute,
Charlotte, NC
Levine Cancer Institute,
Charlotte, NC
Last modified: August 10, 2023